home.social

#marketexpectations — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #marketexpectations, aggregated by home.social.

  1. Strong demand for Botox, generating $1.49 billion in quarterly revenue, persists despite intense competition. AbbVie's 2024 earnings per share forecast falls in the range of $11.05 - $11.25 billion, aligning with analyst estimates at the upper end of this range, specifically at $11.24. #AbbVie #FinancialResults #EarningsReport #Humira #ImmunologyProducts #Botox #RevenueForecast #2024Projection #MarketExpectations

  2. Strong demand for Botox, generating $1.49 billion in quarterly revenue, persists despite intense competition. AbbVie's 2024 earnings per share forecast falls in the range of $11.05 - $11.25 billion, aligning with analyst estimates at the upper end of this range, specifically at $11.24. #AbbVie #FinancialResults #EarningsReport #Humira #ImmunologyProducts #Botox #RevenueForecast #2024Projection #MarketExpectations

  3. The negative outlook stemming from CVS Health's decision to delist Humira poses a challenge, but AbbVie aims to counter the lost revenue with new immunology products Skyrizi and Rinvoq. In its 2027 projection, AbbVie raised the revenue forecast for these drugs from $21 billion to $27 billion.#AbbVie #FinancialResults #EarningsReport #Humira #ImmunologyProducts #Botox #RevenueForecast #2024Projection #MarketExpectations

  4. The negative outlook stemming from CVS Health's decision to delist Humira poses a challenge, but AbbVie aims to counter the lost revenue with new immunology products Skyrizi and Rinvoq. In its 2027 projection, AbbVie raised the revenue forecast for these drugs from $21 billion to $27 billion.#AbbVie #FinancialResults #EarningsReport #Humira #ImmunologyProducts #Botox #RevenueForecast #2024Projection #MarketExpectations